Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020
Published by Elsevier Ltd..
BACKGROUND: Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance systems. TTS incidence rates (IRs) in the United States (U.S.) are needed to contextualize reports following COVID-19 vaccination.
METHODS: We estimated annual and monthly IRs of overall TTS, common site TTS, and unusual site TTS for adults aged 18-64 years in Carelon Research and MarketScan commercial claims (2017-Oct 2020), CVS Health and Optum commercial claims (2019-Oct 2020), and adults aged ≥ 65 years using CMS Medicare claims (2019-Oct 2020); IRs were stratified by age, sex, and race/ethnicity (CMS Medicare).
RESULTS: Across data sources, annual IRs for overall TTS were similar between Jan-Dec 2019 and Jan-Oct 2020. Rates were higher in Medicare (IRs: 370.72 and 365.63 per 100,000 person-years for 2019 and 2020, respectively) than commercial data sources (MarketScan IRs: 24.21 and 24.06 per 100,000 person-years; Optum IRs: 32.60 and 31.29 per 100,000 person-years; Carelon Research IRs: 24.46 and 26.16 per 100,000 person-years; CVS Health IRs: 30.31 and 30.25 per 100,000 person-years). Across years and databases, common site TTS IRs increased with age and were higher among males. Among adults aged ≥ 65 years, the common site TTS IR was highest among non-Hispanic black adults. Annual unusual site TTS IRs ranged between 2.02 and 3.04 (commercial) and 12.49 (Medicare) per 100,000 person-years for Jan-Dec 2019; IRs ranged between 1.53 and 2.67 (commercial) and 11.57 (Medicare) per 100,000 person-years for Jan-Oct 2020. Unusual site TTS IRs were higher in males and increased with age in commercial data sources; among adults aged ≥ 65 years, IRs decreased with age and were highest among non-Hispanic American Indian/Alaska native adults.
CONCLUSION: TTS IRs were generally similar across years, higher for males, and increased with age. These rates may contribute to surveillance of post-vaccination TTS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Vaccine - 42(2024), 8 vom: 19. März, Seite 2004-2010 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lloyd, Patricia C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Background rates |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2024.02.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368782328 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368782328 | ||
| 003 | DE-627 | ||
| 005 | 20240318234433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2024.02.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM368782328 | ||
| 035 | |a (NLM)38388240 | ||
| 035 | |a (PII)S0264-410X(24)00164-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lloyd, Patricia C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance systems. TTS incidence rates (IRs) in the United States (U.S.) are needed to contextualize reports following COVID-19 vaccination | ||
| 520 | |a METHODS: We estimated annual and monthly IRs of overall TTS, common site TTS, and unusual site TTS for adults aged 18-64 years in Carelon Research and MarketScan commercial claims (2017-Oct 2020), CVS Health and Optum commercial claims (2019-Oct 2020), and adults aged ≥ 65 years using CMS Medicare claims (2019-Oct 2020); IRs were stratified by age, sex, and race/ethnicity (CMS Medicare) | ||
| 520 | |a RESULTS: Across data sources, annual IRs for overall TTS were similar between Jan-Dec 2019 and Jan-Oct 2020. Rates were higher in Medicare (IRs: 370.72 and 365.63 per 100,000 person-years for 2019 and 2020, respectively) than commercial data sources (MarketScan IRs: 24.21 and 24.06 per 100,000 person-years; Optum IRs: 32.60 and 31.29 per 100,000 person-years; Carelon Research IRs: 24.46 and 26.16 per 100,000 person-years; CVS Health IRs: 30.31 and 30.25 per 100,000 person-years). Across years and databases, common site TTS IRs increased with age and were higher among males. Among adults aged ≥ 65 years, the common site TTS IR was highest among non-Hispanic black adults. Annual unusual site TTS IRs ranged between 2.02 and 3.04 (commercial) and 12.49 (Medicare) per 100,000 person-years for Jan-Dec 2019; IRs ranged between 1.53 and 2.67 (commercial) and 11.57 (Medicare) per 100,000 person-years for Jan-Oct 2020. Unusual site TTS IRs were higher in males and increased with age in commercial data sources; among adults aged ≥ 65 years, IRs decreased with age and were highest among non-Hispanic American Indian/Alaska native adults | ||
| 520 | |a CONCLUSION: TTS IRs were generally similar across years, higher for males, and increased with age. These rates may contribute to surveillance of post-vaccination TTS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Background rates | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a Thrombosis with thrombocytopenia syndrome (TTS) | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Lufkin, Bradley |e verfasserin |4 aut | |
| 700 | 1 | |a Moll, Keran |e verfasserin |4 aut | |
| 700 | 1 | |a Ogilvie, Rachel P |e verfasserin |4 aut | |
| 700 | 1 | |a McMahill-Walraven, Cheryl N |e verfasserin |4 aut | |
| 700 | 1 | |a Beachler, Daniel C |e verfasserin |4 aut | |
| 700 | 1 | |a Kelman, Jeffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Xiangyu |e verfasserin |4 aut | |
| 700 | 1 | |a Hobbi, Shayan |e verfasserin |4 aut | |
| 700 | 1 | |a Amend, Kandace L |e verfasserin |4 aut | |
| 700 | 1 | |a Djibo, Djeneba Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Shangguan, Shanlai |e verfasserin |4 aut | |
| 700 | 1 | |a Shoaibi, Azadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Minya |e verfasserin |4 aut | |
| 700 | 1 | |a Secora, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Cindy Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Kowarski, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Chillarige, Yoganand |e verfasserin |4 aut | |
| 700 | 1 | |a Forshee, Richard A |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Steven A |e verfasserin |4 aut | |
| 700 | 1 | |a Muthuri, Stella |e verfasserin |4 aut | |
| 700 | 1 | |a Seeger, John D |e verfasserin |4 aut | |
| 700 | 1 | |a Kline, Annemarie |e verfasserin |4 aut | |
| 700 | 1 | |a Reich, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a MaCurdy, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Hui Lee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 42(2024), 8 vom: 19. März, Seite 2004-2010 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:8 |g day:19 |g month:03 |g pages:2004-2010 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2024.02.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 8 |b 19 |c 03 |h 2004-2010 | ||